<p>Iridex Corporation has announced the publication of an independent, retrospective study in the journal Ophthalmology and Therapy evaluating the safety and efficacy of retreatment with transscleral laser treatment using MicroPulse® technology (MicroPulse TLT) in glaucoma management. The study demonstrates that retreatment with MicroPulse TLT can safely and effectively further reduce intraocular pressure (IOP) in patients with glaucoma. According to the company, these clinical data support MicroPulse TLT as a repeatable, non-incisional therapy option for patients at various stages of glaucoma. The results of the study have already been published. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRIDEX Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597369-en) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

IRIX

<p>Iridex Corporation announced a study published in Ophthalmology and Therapy, showing that MicroPulse TLT safely and effectively lowers intraocular pressure in glaucoma patients. The study supports MicroPulse TLT as a repeatable, non-incisional therapy for various stages of glaucoma. This announcement was made via GlobeNewswire on December 11, 2025.</p>

Iridex Announces Study Showing MicroPulse TLT Safely Lowers Eye Pressure in Glaucoma Patients